ssa: inclusion criteria: * male or female participants 18 years of age and older * participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. * healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * capable of giving signed informed consent as described in the protocol. * for participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1). * for participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modrna sars-cov-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before visit 1 (day 1). * for participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration. ssa:

ssa: inclusion criteria: * male or female participants 18 years of age and older * participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. * healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. * capable of giving signed informed consent as described in the protocol. * for participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1). * for participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modrna sars-cov-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before visit 1 (day 1). * for participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration. ssa:

ssa: inclusion criteria: male or female participants 18 years of age and older participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. capable of giving signed informed consent as described in the protocol. for participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1). for participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modrna sars-cov-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before visit 1 (day 1). for participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration. ssa:

ssa: inclusion criteria: male or female participants 18 years of age and older participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. capable of giving signed informed consent as described in the protocol. for participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1). for participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modrna sars-cov-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before visit 1 (day 1). for participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration. ssa:

inclusion criteria: male or female participants 18 years of age and older participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. capable of giving signed informed consent as described in the protocol. for participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1). for participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modrna sars-cov-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before visit 1 (day 1). for participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration.

inclusion criteria: male or female participants 18 years of age and older participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. capable of giving signed informed consent as described in the protocol. for participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1). for participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modrna sars-cov-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before visit 1 (day 1). for participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration.

inclusion criteria: male or female participants 18 through 64 years of age participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. capable of giving signed informed consent as described in the protocol. participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1).

inclusion criteria: male or female participants 18 through 64 years of age participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures. healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. capable of giving signed informed consent as described in the protocol. participants who have received 3 prior doses of 30 µg bnt162b2, with the last dose being 150 to 365 days before visit 1 (day 1).